TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04658797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A Daily Disposable Contact Lens
Description: Daily Disposable Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vision Spectacle for Vision Correction
Description: Single Vision Spectacle
Study: NCT06729398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: NIRS is placed on the frontoparietal once the neonates born in the delivery room until 72 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SafeboosC
Description: SafeboosC treatment guideline is used to maintain normal value of cerebral rStO2.
Study: NCT03632941

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VRP-HER2
Description: VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRP-HER2
Description: VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
Study: NCT05202873

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait analysis
Description: Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the Walk+ protocol, in which the participant navigates a 7-meter hallway six times, completing three round trips with necessary turns at each end to change direction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gait analysis
Description: Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the Walk+ protocol, in which the participant navigates a 7-meter hallway six times, completing three round trips with necessary turns at each end to change direction.
Study: NCT03514316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel Gingivectomy
Description: The patients were anesthetized in the area around the teeth which were to undergo the procedure with local anesthesia (Drug: 2% lidocaine and 1:80,000 adrenaline). Initially, the Periodontal Probing Depth was measured and when sufficient anesthesia was achieved, biologic width calculation was done by the trans-gingival probing method. Once the amount of gingival tissue to be excised was demarcated, an external bevel incision was performed by using a scalpel blade (Device: scalpel blade No.15) and the gingival tissue was excised. Left out tissue tags and any beads of granulations tissue were removed to attain a smooth surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Gingivectomy
Description: In the Laser Gingivectomy group, the procedure was performed by using a 810 nm diode laser (Device: 810 nm FOX III diode laser) . Though a local anesthetic gel is sufficient considering that the procedure is minimally invasive, the area was adequately anesthetized with 2% lidocaine and 1:80,000 adrenaline. The laser unit, comprising of a 300 μm disposable tip, was used in a contact mode with a setting of 1 to 1.5 watts in continuous mode along the demarcated area with a paint brush like strokes progressing slowly to remove the gingival tissue and expose adequate amount of tooth structure. High-volume suction was used to evacuate the laser plume and charred odor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical periodontal treatment
Description: In all subjects of the Control Group a full-mouth periodontal debridement was performed at baseline, 1 and 3 months with an ultrasonic scaler. Chlorhexidine prophylaxis (0.05% chlorhexidine gluconate) was also administered twice a day for 2 weeks after the periodontal treatment. Oral-hygiene instructions were reinforced again.
Study: NCT04658797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personal Facemask
Description: Personal Facemask

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Facemask
Description: Personal Facemask
Study: NCT00910598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glatiramer acetate
Description: 20 mg daily s.c. for 1 year
Study: NCT02948829

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.
Study: NCT05885451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as SC injection
Study: NCT00814138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly
Study: NCT01222208

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nutrition with dextrose and pressurized whey protein
Description: Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral Parenteral Nutrition
Description: Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
Study: NCT00327223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imexon
Study: NCT04175132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foliglurax
Description: Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foliglurax
Description: Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg
Study: NCT03485534

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Viread 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil
Description: Virehepa 245mg
Study: NCT00737100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat
Description: patient to receive placebo matching active drug once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 5 mcg
Description: patient to recieve high dose tiotropium once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide-low dose-2.5mcg
Description: patient to receive low dose tiotropium once daily
Study: NCT01414478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Shake
Description: Protein shake contains 30 grams of protein in 11 fluid ounces.
Study: NCT04474262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03099460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular electroacupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
Study: NCT01768780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine
Description: The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle.
Study: NCT01301261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: Sugammadex 2 mg/kg when a two count of train of four appears

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex 4 mg/kg
Description: Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex 16mg/kg
Description: Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
Study: NCT00275171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human thyrotropin (Thyrogen)
Description: 0.1 mg rhTSH administered intramuscularly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human TSH
Description: 0.1 mg rhTSH administered intramuscularly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline = placebo
Description: 0.1 mg isotonic saline injected intramuscularly
Study: NCT04281082

Intervention type: DRUG
Intervention: ursofalk
Description: To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
Study: NCT02962310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Rosuvastatin Calcium Tablets 40 mg
Description: oral, crossover

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 40 mg Tablets of AstraZeneca LP, USA
Description: oral, crossover
Study: NCT01361750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric tube
Description: the stomach will be cut into a narrowed tube-shape conduit
Study: NCT05366595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral zinc sulfate
Description: Oral zinc sulfate at dose 10 to 20 mg daily for 10 days
Study: NCT03721224

Intervention type: DIAGNOSTIC_TEST
Intervention: Kiddie Schedule for Affective Disorders and Schizophrenia
Description: Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview

Intervention type: DIAGNOSTIC_TEST
Intervention: Kiddie Schedule for Affective Disorders and Schizophrenia
Description: Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview
Study: NCT01057355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS and/or ERCP with ethanol injections of pancreatic cyst
Description: Lavage of cyst with 80% ethanol
Study: NCT04007965

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Posterior Capsulorhexis
Description: Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic Posterior Capsulorhexis
Description: Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
Study: NCT02725658

Intervention type: DEVICE
Group type: OTHER
Intervention: DOSI
Description: Breast tissue properties scanning
Study: NCT03566095

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching and Voices for Food Kit
Description: Community Coaching and Voices for Food Kit

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Voices for Food Kit
Description: Voices for Food Kit
Study: NCT01979874

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega
Description: Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ProOmega Placebo
Description: Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
Study: NCT01961414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
Study: NCT01699048

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hybrid (MIDCAB+PCI)
Description: Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCI
Description: Multi-vessel PCI with DES

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CABG
Description: Coronary artery bypass graft (CABG) treatment
Study: NCT02346708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TMS
Description: real treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: placebo treatment
Study: NCT04758013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural injection through thoracic epidural catheter
Description: The investigators inject drugs through a catheter inserted into the thoracic epidural space to control pain after surgery in patients undergoing gastric surgery by laparoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Without epidural injection
Description: The investigators don't epidural injection to find out the effect of only inter-abdominal pressure on intracranial pressure.
Study: NCT03928054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping and therapeutic alliance
Description: bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping and therapeutic alliance
Description: bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
Study: NCT00614874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: 2mg, 4mg, 8mg
Study: NCT01687114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cranberry juice
Description: 27% cranberry juice
Study: NCT04488913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RACE-IT Pathway
Description: This care pathway includes the evaluation of suspected acute coronary syndrome with high-sensitivity troponin I testing and further prognostication as needed with a modified HEART score

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care protocol that uses the 99th percentile troponin values for evaluation of suspected acute coronary syndrome and further prognostication using the HEART score
Study: NCT03286387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional brain imaging without any contrast agent
Description: During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min).
Study: NCT02593877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VHA algorithm
Description: Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
Study: NCT00233480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 10mg PO QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo Qd x 3 months
Study: NCT04086277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Intrapartum Support
Description: Received the usual obstetric care plus continuous intrapartum support that was provided by a Bachelor of Nursing and Obstetrics who received prior training by a professional doula.
Study: NCT00278447

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Management for substance abuse
Description: Referral to primary medical care \& longitudinal, multidisciplinary care for persons with substance dependence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Referral to primary medical care for persons with substance dependence.
Study: NCT03563326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting EpCAM
Description: Biological: CAR-T cells targeting EpCAM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy: determined by medical Oncologist

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy: determined by medical Oncologist
Study: NCT01736943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
Study: NCT00387426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study: NCT03518190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared spectroscopy (ODP)
Description: Infrared spectroscopy device will be used to detect non-visible pressure injuries
Study: NCT00053885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: oral
Study: NCT03472131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Posterolateral Approach and Debridement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titanium cage insertion supplemented by screw fixation
Study: NCT02457195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Application granisetron transdermal patch preoperatively
Study: NCT01703494

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham Fecal Microbiota Transplantation
Description: After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
Study: NCT03760224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WhatsApp group
Description: WhatsApp group will allow real-time group discussion for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS group
Description: SMS group for 8 weeks